Related Experiment Videos
[Scleromyxedema: immunosuppressive therapy with cyclophosphamide]
Summary
Scleromyxedema treatment with high-dose intravenous cyclophosphamide pulse therapy and alternate-day prednisone showed excellent results. This approach dramatically improved symptoms and prevented recurrence over a 12-month follow-up.
Area of Science:
- Dermatology
- Rheumatology
- Oncology
Background:
- Scleromyxedema is a rare multisystemic disorder characterized by skin sclerosis, myopathy, arthritis, and potential cardiovascular/cerebrovascular involvement.
- The condition is associated with an abnormal monoclonal immunoglobulin G (IgG) protein.
- Limited established therapeutic options exist for scleromyxedema, necessitating investigation into novel treatment strategies.
Observation:
- A 59-year-old male presented with typical scleromyxedema manifestations including lichenoid papules, excessive skin folds, generalized skin sclerosis, myopathy, arthritis, and monoclonal IgG.
- The patient exhibited significant systemic involvement, posing a challenge for management.
Findings:
- A therapeutic trial utilizing monthly high-dose intravenous cyclophosphamide pulse therapy combined with alternate-day low-dose prednisone was initiated.
- The treatment resulted in excellent outcomes, with dramatic improvement in both subjective and objective symptoms.
- Twelve-month follow-up revealed no disease recurrence, indicating sustained efficacy.
Implications:
- High-dose intravenous cyclophosphamide pulse therapy with prednisone represents a promising therapeutic approach for severe scleromyxedema.
- This regimen may offer a viable option for managing the systemic manifestations and preventing disease progression.
- Further research is warranted to confirm these findings in a larger cohort and establish optimal treatment protocols.